Currently, the first-line systemic treatment for advanced-stage NSCLC is targeted therapy for those who bear driver oncogene mutations in tumor, for example, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for patients with drug-activating mutations in the EGFR gene [1]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.